(Q38802932)

6 September 2017

title

The assessment of HER2 status in breast cancer: the past, the present, and the future (English)

1 reference

6 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Hiroaki Nitta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Craig Allred

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Suzan Jewell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter Banks

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Eslie Dennis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Thomas M Grogan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

7 April 2016

1 reference

6 September 2017

published in

Pathology International

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

313-324

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

3 June 2020

cites work

1 reference

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

21 January 2018

1 reference

Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification

21 January 2018

1 reference

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

21 January 2018

1 reference

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.

21 January 2018

1 reference

HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.

21 January 2018

1 reference

Quantitative analysis of diagnostic guidelines for HER2-status assessment

21 January 2018

1 reference

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

21 January 2018

1 reference

Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management.

21 January 2018

1 reference

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma

21 January 2018

1 reference

Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.

21 January 2018

1 reference

Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues

21 January 2018

1 reference

The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation.

21 January 2018

1 reference

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

21 January 2018

1 reference

HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

Delay to formalin fixation effect on breast biomarkers

21 January 2018

1 reference

Delay to formalin fixation effect on HER2 test in breast cancer by dual-color silver-enhanced in situ hybridization (Dual-ISH).

21 January 2018

1 reference

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

21 January 2018

1 reference

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

21 January 2018

1 reference

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

21 January 2018

1 reference

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

21 January 2018

1 reference

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

21 January 2018

1 reference

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

21 January 2018

1 reference

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

21 January 2018

1 reference

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

21 January 2018

1 reference

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

21 January 2018

1 reference

'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases

21 January 2018

1 reference

Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.

21 January 2018

1 reference

Genetic heterogeneity in HER2 testing may influence therapy eligibility.

21 January 2018

1 reference

Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

21 January 2018

1 reference

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

21 January 2018

1 reference

Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer

21 January 2018

1 reference

Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis

21 January 2018

1 reference

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

21 January 2018

1 reference

The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines

21 January 2018

1 reference

Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.

21 January 2018

1 reference

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

21 January 2018

1 reference

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.

21 January 2018

1 reference

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.

21 January 2018

1 reference

Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.

21 January 2018

1 reference

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

21 January 2018

1 reference

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

21 January 2018

1 reference

Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification

21 January 2018

1 reference

Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.

21 January 2018

1 reference

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide

21 January 2018

1 reference

Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.

21 January 2018

1 reference

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing

21 January 2018

1 reference

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/PIN.12407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27061008%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference